Tag Archives: Medtech

First Coast Tech Hubs Gather @ RESI Boston

16 Aug

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The First Coast Innovator’s Gathering is a new component of the Redefining Early Stage Investments (RESI) Conference Series which was requested by the investors and strategic channel partners who routinely attend RESI. Many of these partners wanted LSN to bring the “earliest stage” companies so that they can identify them and get them on their radar screens in order to start a dialogue that can result in a future partnership. The First Coast Innovator’s Gathering focuses on tech hubs and companies from the First Coast of life sciences: DC, MD, PA, NJ, NY, RI, CT, and MA. Dozens of tech hubs will be attending RESI to take a spot in the exhibit hall and showcase the new technologies being developed at their institution or facility. This fall, RESI will expand to include the earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding.

This RESI event offers exhibit tables to the incubators, accelerators, tech transfer offices, university translation initiatives, hospitals, research labs and their constituents, with space for incubator members’ poster boards (5 poster boards for each tech hub). LSN’s network of early-stage global investors will have access to all the key players in one place to learn about the iterative, breakthrough, and transformative technology coming out of the First Coast region.

Stetson Family Office, a Title Sponsor of RESI and a supporter of the Innovator’s Gathering, is pioneering new global funding initiatives and platforms to help the early stage players move faster through the development cycle. See below for the tech hubs that are confirmed to be part of the First Coast Innovator’s Gathering. Tech hub members are also eligible to apply for free to the First Coast Innovation Challenge to pitch in front of a panel of investors. The deadline for applications is Friday August 17th – that’s tomorrow! If you’d like to make a 7-minute pitch to investors at RESI, it’s not too late to sign up. We hope you will join us at RESI Boston on September 6th to see more. Click to see the confirmed First Coast Innovator’s Gathering participants

Massachusetts

Connecticut / Rhode Island

New York City / New Jersey

Pennsylvania

Maryland

Tags: , , , , , , , , , , , , , , , , , , ,

China PE Firm Invests Up to $40M Per Company In Medtech, Diagnostics, and Digital Health

19 Jul

A private equity firm headquartered in China with additional offices throughout China and Hong Kong provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , ,

Hot Investor Mandate: Newly Established VC Fund Invests in Innovative Digital Health and Medtech/Diagnostics Technologies with Software Components

12 Jul

A new venture fund started investing in pre-seed, seed and Series A rounds. The firm’s main investment areas are in companies that advance and improve human health through novel models of care delivery and in companies that are at the cutting-edge of frontier technology, such as neurotech, brain/machine interfaces, genomics and AI. The firm will consider digital health companies as well as diagnostics and medical device companies, as long as they have a software component. The firm will only invest in companies with disruptive technology, not incremental innovations. The firm will invest between $.1-1.5M in the initial investment, with the possibility of participating in following rounds. The firm is willing to lead or co-invest, has made 7 investments to date and is looking to invest in 4-6 companies a year.

The firm will consider digital health companies that are focused on improving patient care. Ideally, companies will already have a pilot with some outcomes-based data indicating traction. The firm is also interested in medical device companies, but will only invest if there is a significant software and/or radical innovation component. The firm will also consider diagnostics, such as genomics-based technologies, but not in vitro diagnostics. The firm will not invest in traditional therapeutics (i.e. small molecule or biologics) companies but will consider software-as-medicine and bioelectronic medicine.

Due to the firm’s preference for cutting-edge technology, the firm prefers that there be at least one technical expert in the company leadership. If acting as a lead investor, the firm will take a board or board observer seat. The firm prefers to be an active investor, providing multi-faceted support to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

5 Jul

A venture capital firm that was founded in 2006 and is based in the Southern USA has managed $400 million in total assets, and recently closed its sixth fund. The firm typically makes equity investments into enterprise software, medical devices, and healthcare IT companies in the seed, series A, series B and series C stages. The typical investment size ranges from $3 million to $10+ million per company. The allocation numbers will vary over the next 6-9 months. For early-stage investments, the firm primarily invests in companies based in Texas, but they will also consider opportunities in the Southwest of the US.

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.

The firm generally seeks to invest in private companies. The firm will consider pre-revenue companies and has no specific requirements for the company’s management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , ,

Hot Investor Mandate 1: Toronto-Based Single Family Office Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies

3 May

A single family office based in Toronto, Ontario has its main focus on real estate and mining, but is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space. The firm may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor 2: Venture Arm of Swiss Foundation Invests Globally in Disruptive Medtech and Digital Health Companies in Trauma and Orthopedic Surgeries

22 Mar

A venture arm of a Switzerland-based foundation invests in start-ups that fundamentally improve patient care in the area of orthopedic, spine & trauma surgery. While the firm will invest globally, the current focus is on companies located in North America, Europe and Israel. The firm prefers to participate in Series A rounds, investing between $1-2.5M with the potential to provide additional capital in later rounds. The firm’s sole investor is their parent foundation, a surgeon-led, not-for-profit organization. The foundation has a global network of more than 16,000 healthcare professionals and scientists in over 100 countries specialized in the treatment of trauma and disorders of the musculoskeletal system.

The firm looks to fund companies with disruptive technologies in medical devices, diagnostics, and healthcare IT/digital health in the trauma and orthopedic surgery space. This includes technologies for before, during or after surgery, such as imaging, surgical tools, implantable devices and clinical data management. However, the firm is not currently looking to fund any regenerative medicine or tissue engineering applications within this space. If a medical device or diagnostic, companies should have a working prototype and preclinical data, while healthcare IT/digital health companies should have a running MVP as well as the ability to show market traction.

The firm invests in teams and companies that solve fundamental problems. The firm is looking for a clear market understanding and strong USP.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , ,

Hot Investor Mandate 3: Canada-Based Investment Group Provides Seed Funding to Medtech, Cleantech, and IT Sectors Across North America, With Canadian Focus

22 Mar

A venture capital fund, angel group, and registered exempt market dealer based in Toronto, Ontario is affiliated with early stage venture funds, including their accelerator fund I and II as well as an angel group. The firm usually acts a lead investor in rounds of up to $2M, with between $300K – $750K coming from the first-mentioned fund, and with additional capital usually coming from the angel group or other family offices or institutional investment partners. The firm has also participated, and will continue to participate, in larger syndicated investment rounds. The firm prefers to lead priced equity rounds and does not usually make investments in uncapped convertible debt or SAFEs (Simple Agreements for Future Equity).

Annually, the firm works with, and makes investments in, 8 to 12 early stage (Seed and Series A) companies in the IT, CleanTech and MedTech sectors. In the MedTech sector, the firm typically does not invest in products with a complex regulatory pathway. The firm is also interested in platform technologies and R&D service/tools companies. Historic MedTech investments include investments in (i) a company which has developed an imaging agent that illuminates tumors both at the surgery planning phase and inside the operating room, (ii) a company that manufactures the world’s only natural, non-toxic, mono-disperse nano particle extracted from sweet corn which has applications in the personal care/cosmetics, nutraceutical and biomedical spaces; and (iii) a company that has a proprietary in silico software platform that maps interactions of drug compounds against the human proteome to identify drug efficacy, side effects and toxicity risks.

The firm is focused on Canadian companies, but will also evaluate U.S.-based and international companies if there is a potential investment fit. The firm’s principals have significant technology, financial and legal experience. The firm’s ideal investment candidate is a company that will benefit from and can leverage this experience and network and to which the firm can provide additional long-term value beyond its cash investment. The firm tries to avoid taking on technology risk but will take on some commercialization risk and prefers entrepreneurs that have had at least one ‘win’ (or event better, at least one ‘loss’)

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

← Older Entries

%d bloggers like this: